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Conclusion: In our cohort, IFRT did not result to be 
associated to a PFS or OS benefit vs CT alone in the overall 
population. IFRT seemed to provide a survival benefit at 3 
and 5 years compared to CT alone (92.3% vs 61.9% and 79.1% 
vs 51.6%) in patients with stage I-II disease at relapse and 
with persistent disease prior to ASCT. A larger sample size is 
needed to further explore the effect of IFRT in this particular 
setting. 
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Purpose or Objective: Desmoplastic small round cell tumor 
(DSRCT) is a rare peritoneal tumor affecting predominantly 
children and young adult Caucasian males with a high rate of 
local failure after surgery. We performed a multicentric 
retrospective study to identify the prognostic impact of 
adjuvant abdominal radiotherapy. 
 
Material and Methods: All patients treated for primary 
abdominal DSRCT in 8 French centers from 1991 to 2014 were 
included. Patients were retrospectively staged into 3 groups: 
group A treated with adjuvant radiotherapy (RT) after 
cytoreductive surgery, group B without RT after 
cytoreductive surgery and group C by exclusive 
chemotherapy. Peritoneal progression-free survival (PPFS), 
progression-free survival (PFS) and overall survival (OS) were 
evaluated. We also performed a direct comparison between 
group A and B to evaluate RT after cytoreductive surgery. RT 
was also evaluated according to completeness of surgery: 
complete cytoreductive surgery (CCS) or incomplete 
cytoreductive surgery (ICS). 
 
Results: Thirty-seven (35.9%), thirty-six (34.9%) and thirty 
(28.0%) patients were included in group A, B and C, 
respectively. Three-year OS was 61.2% (41.0-76.0), 37.6% 
(22.0-53.1), and 17.3% (6.3-32.8) for group A, B and C, 
respectively. OS, PPFS and PFS differed significantly between 
the 3 groups (p<0.001; p<0.001 and p<0.001, respectively). 
OS and PPFS were higher in group A (RT group) compared to 
group B (no RT group) (p=0.045 and p=0.006, respectively). 
Three-year PPFS was 23.8% (10.3-40.4) for group A and 
12.51% (4.0-26.2) for group B. After CCS, RT improved PPFS 
(p=0.024) but differences in OS and PFS were not significant 
(p=0.40 and p=0.30, respectively). After ICS, RT improved OS 
(p=0.044). A trend of PPFS and PFS increase was observed but 
the difference was not statistically significant (p=0.073 and 
p=0.076). 
 
Conclusion: Adjuvant radiotherapy as part of multimodal 
treatment seems to confer oncological benefits for patients 
treated for abdominal DSRCT after cytoreductive surgery and 
perioperative chemotherapy.This study is the largest series 
evaluating DSRCT treatment and the first of its kind 
comparing patients who received RT after cytoreductive 
surgery with patients who did not. 
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Purpose or Objective: To compare Quality of Life (QoL) 
outcomes in patients (pts) with Malignant Spinal Cord 
Compression (MSCC) not proceeding with surgical 
decompression and treated by External Beam Radiation 
Therapy (EBRT) with one of two Fractionation Schedules (FS). 
 
Material and Methods: ICORG 05-03 was an ICH-GCP 
compliant prospective (1.1) randomised non-inferiority phase 
III trial comparing two FS: arm 1 (control): 20Gy/5 Fractions 
(#) vs. arm 2 (experimental): 10Gy/1#, with 80% power, 5% 
significant level and 0.4 non-inferiority margin. While the 
primary end point of this trial (previously presented (ASTRO 
2014)) was change in mobility at 5 weeks (wks), the current 
focus is on a secondary endpoint, QoL (EORTC QLQ-C30 
questionnaire).  
 
Results: From 2006 to 2014, 5 institutions accrued 115 
eligible pts (2 non-eligible pts, no treatment allocation 
violation). 70 pts with QoL data at 5 wks were evaluable. 
Baseline characteristics were balanced between arms [♀/♂: 
30/40, median age: 69 (range: 30-87)]. Analysis showed a 
statistically significant benefit of radiotherapy (RT) for ‘Pain 
interfered with daily activities’ but not for Overall OoL. 
There was no statistically significant benefit between arms 
for either: 1. Overall QoL (mean change from pre-treatment 
.52 in arm 1 vs. .21 in arm 2; 95% CI: -0.84 – 1.45, p = 0.596); 
2. Pain interfered with daily activities (mean change: .84 in 
arm 1 vs. 1.00 in arm 2; 95% CI: -0.66 – .98, p = 0.698). A 
non-planned exploratory regression analysis checked for 
independent prognostic factors for less pain at 5 wks. 
Multiple regression analysis revealed baseline pain as the 
strongest unique and statistically significant contributor to 
explaining less pain at 5-wks (beta = -0.63; p=0.002).  
Exploratory analyses were also conducted to characterise pts 
dying at <5 wks,who might not benefit from RT. Primary 
malignancy (Chi-square test: Χ2 (3, n=106) = 15.6, p = 0.001, 
phi = 0.38) and initial mobility status (Chi-square test, Χ2 (2, 
n=106) = 11.0, p = 0.004, phi = 0.32.) were found to be 
associated with a life expectancy <5 wks. 67% of lung and 13% 
of breast cancer pts died before 5 wks, as did 49% of bed-
bound and 15% of pts who could walk unaided.  
 
Conclusion: With respect to QoL, primary RT significantly 
improves the pain related variables used in the trial, with 
10Gy/1# FS being at least equivalent to 20Gy/5#. Baseline 
pain is the most significant independent prognostic factor for 
less pain at 5 wks. Tumour site and mobility should be 
considered when offering RT treatment to similar pts. 
 
 
 
 
